HDAC9 and prostate carcinoma: Removal of HDAC-mediated transcriptionalsilencing via HDAC inhibitors may allow activation of PPARγ, as suggested by in vitro and in vivostudies of combined therapy of prostate cancer with HDAC inhibitors and PPARγ agonists [85].